Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- JAMA oncology
- Publicado em
- 1 fev 2026
- Citações
- 9
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial
George Q Zhang, Jeffrey A Meyerhardt, Qian Shi, Tyler Twombly, Levi Pederson, Chao Ma, Juha P Väyrynen, Melissa Zhao, Yasutoshi Takashima, Ardaman Shergill et al.
Descritores MeSH
- Colonic Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Circulating Tumor DNA
- Celecoxib
- Female
- Fluorouracil
- Humans
- Male
- Middle Aged
- Neoplasm Staging
Veja também
Estudos relacionados
- Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial
- Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)
- Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12)
- Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis